{"title":"[Efficacy and tolerance of risperidone in various doses (report of a study)].","authors":"E Cesková, J Svestka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses. According to the maximal daily dose achieved the risperidone group was divided in 4 subgroups and the risperidone efficacy and tolerability in these groups were compared both mutually and in relation to the baseline. With all doses a good global antipsychotic efficacy has been observed. There were no statistically significant differences in influencing of productive or negative symptoms with exception of significantly more pronounced reduction of productive catatonic symptoms with 2 < max < or = 5 mg in comparison with doses higher than 15 mg daily. Extrapyramidal symptoms were less frequent with lower doses: with 2 < max < or = 5 mg significantly lower occurrence of increased muscle tonus and tremor was found than with higher doses. With maximal daily doses above 10 mg antiparkinson drugs had to be applied in more patients and in the case of trihexyphenidyl this difference reached a statistically significant level.</p>","PeriodicalId":39713,"journal":{"name":"Ceska a Slovenska Psychiatrie","volume":"92 1","pages":"50-6"},"PeriodicalIF":0.0000,"publicationDate":"1996-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Psychiatrie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses. According to the maximal daily dose achieved the risperidone group was divided in 4 subgroups and the risperidone efficacy and tolerability in these groups were compared both mutually and in relation to the baseline. With all doses a good global antipsychotic efficacy has been observed. There were no statistically significant differences in influencing of productive or negative symptoms with exception of significantly more pronounced reduction of productive catatonic symptoms with 2 < max < or = 5 mg in comparison with doses higher than 15 mg daily. Extrapyramidal symptoms were less frequent with lower doses: with 2 < max < or = 5 mg significantly lower occurrence of increased muscle tonus and tremor was found than with higher doses. With maximal daily doses above 10 mg antiparkinson drugs had to be applied in more patients and in the case of trihexyphenidyl this difference reached a statistically significant level.
在两项双盲研究中,利培酮与氟哌啶醇和奋那嗪治疗精神分裂症。根据达到的最大日剂量将利培酮组分为4个亚组,相互比较各组利培酮的疗效和耐受性,并与基线进行比较。所有剂量均有良好的整体抗精神病疗效。在对生产性或阴性症状的影响方面,没有统计学上的显著差异,除了2 < max <或= 5mg与每日高于15mg的剂量相比,生产性紧张性症状的减轻更为显著。较低剂量时锥体外系症状较少:2 < max <或= 5mg时,肌肉张力增加和震颤的发生率明显低于较高剂量时。每日最大剂量超过10毫克的抗帕金森药物必须应用于更多的患者,在三苯基的情况下,这种差异达到了统计学上显著的水平。
期刊介绍:
Závislost na psychoaktivních látkách je komplexní, multifaktoriální onemocnění, které se vyvine ze souhry genetických predispozic a faktorů okolního prostředí. Vznik a vývoj závisl...